Cargando…

Bioelectrical Stimulation for the Reduction of Inflammation in Inflammatory Bowel Disease

Crohn’s disease and ulcerative colitis are the primary inflammatory bowel diseases (IBDs) affecting the gastrointestinal tract. The current therapy aims at decreasing inflammation and reducing symptoms. This typically requires immune suppression by steroids, thiopurines, methotrexate, or tumor necro...

Descripción completa

Detalles Bibliográficos
Autores principales: Marshall, Ryan, Taylor, Ian, Lahr, Christopher, Abell, Thomas L., Espinoza, Ingrid, Gupta, Nitin K., Gomez, Christian R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4671545/
https://www.ncbi.nlm.nih.gov/pubmed/26692766
http://dx.doi.org/10.4137/CGast.S31779
_version_ 1782404412205957120
author Marshall, Ryan
Taylor, Ian
Lahr, Christopher
Abell, Thomas L.
Espinoza, Ingrid
Gupta, Nitin K.
Gomez, Christian R.
author_facet Marshall, Ryan
Taylor, Ian
Lahr, Christopher
Abell, Thomas L.
Espinoza, Ingrid
Gupta, Nitin K.
Gomez, Christian R.
author_sort Marshall, Ryan
collection PubMed
description Crohn’s disease and ulcerative colitis are the primary inflammatory bowel diseases (IBDs) affecting the gastrointestinal tract. The current therapy aims at decreasing inflammation and reducing symptoms. This typically requires immune suppression by steroids, thiopurines, methotrexate, or tumor necrosis factor inhibitors. Patients may be unreceptive to medical therapy, and some may discontinue the treatment due to adverse effects. Noninvasive, transcutaneous vagus nerve stimulation (VNS) is currently used as a treatment for depression and epilepsy, and it is being investigated for the treatment of conditions such as multiple sclerosis, migraines, and Alzheimer’s disease. Recent studies have demonstrated the importance of splenic and vagus nerve functions in the inflammatory process through the production of certain cytokines. We hypothesize that using transcutaneous VNS via the auricular afferent branch could achieve a selective anti-inflammatory effect on the intestinal wall. This review examines the possibility of using vagal stimulators as a therapy for IBD. This could open the door to novel treatments for numerous vagally mediated diseases characterized by poor responses to current therapies.
format Online
Article
Text
id pubmed-4671545
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Libertas Academica
record_format MEDLINE/PubMed
spelling pubmed-46715452015-12-11 Bioelectrical Stimulation for the Reduction of Inflammation in Inflammatory Bowel Disease Marshall, Ryan Taylor, Ian Lahr, Christopher Abell, Thomas L. Espinoza, Ingrid Gupta, Nitin K. Gomez, Christian R. Clin Med Insights Gastroenterol Commentary Crohn’s disease and ulcerative colitis are the primary inflammatory bowel diseases (IBDs) affecting the gastrointestinal tract. The current therapy aims at decreasing inflammation and reducing symptoms. This typically requires immune suppression by steroids, thiopurines, methotrexate, or tumor necrosis factor inhibitors. Patients may be unreceptive to medical therapy, and some may discontinue the treatment due to adverse effects. Noninvasive, transcutaneous vagus nerve stimulation (VNS) is currently used as a treatment for depression and epilepsy, and it is being investigated for the treatment of conditions such as multiple sclerosis, migraines, and Alzheimer’s disease. Recent studies have demonstrated the importance of splenic and vagus nerve functions in the inflammatory process through the production of certain cytokines. We hypothesize that using transcutaneous VNS via the auricular afferent branch could achieve a selective anti-inflammatory effect on the intestinal wall. This review examines the possibility of using vagal stimulators as a therapy for IBD. This could open the door to novel treatments for numerous vagally mediated diseases characterized by poor responses to current therapies. Libertas Academica 2015-12-06 /pmc/articles/PMC4671545/ /pubmed/26692766 http://dx.doi.org/10.4137/CGast.S31779 Text en © 2015 the author(s), publisher and licensee Libertas Academica Ltd. This is an open-access article distributed under the terms of the Creative Commons CC-BY-NC 3.0 License.
spellingShingle Commentary
Marshall, Ryan
Taylor, Ian
Lahr, Christopher
Abell, Thomas L.
Espinoza, Ingrid
Gupta, Nitin K.
Gomez, Christian R.
Bioelectrical Stimulation for the Reduction of Inflammation in Inflammatory Bowel Disease
title Bioelectrical Stimulation for the Reduction of Inflammation in Inflammatory Bowel Disease
title_full Bioelectrical Stimulation for the Reduction of Inflammation in Inflammatory Bowel Disease
title_fullStr Bioelectrical Stimulation for the Reduction of Inflammation in Inflammatory Bowel Disease
title_full_unstemmed Bioelectrical Stimulation for the Reduction of Inflammation in Inflammatory Bowel Disease
title_short Bioelectrical Stimulation for the Reduction of Inflammation in Inflammatory Bowel Disease
title_sort bioelectrical stimulation for the reduction of inflammation in inflammatory bowel disease
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4671545/
https://www.ncbi.nlm.nih.gov/pubmed/26692766
http://dx.doi.org/10.4137/CGast.S31779
work_keys_str_mv AT marshallryan bioelectricalstimulationforthereductionofinflammationininflammatoryboweldisease
AT taylorian bioelectricalstimulationforthereductionofinflammationininflammatoryboweldisease
AT lahrchristopher bioelectricalstimulationforthereductionofinflammationininflammatoryboweldisease
AT abellthomasl bioelectricalstimulationforthereductionofinflammationininflammatoryboweldisease
AT espinozaingrid bioelectricalstimulationforthereductionofinflammationininflammatoryboweldisease
AT guptanitink bioelectricalstimulationforthereductionofinflammationininflammatoryboweldisease
AT gomezchristianr bioelectricalstimulationforthereductionofinflammationininflammatoryboweldisease